The Swiss Stock Exchange, as well as most European places, started the session on Wednesday on a net rebound, notably thanks to the conclusion of a trade agreement between the United States and Japan. The latter is able to reassure investors in the face of fears of a large -scale customs conflict, while a new day of half -yearly business results awaits them.
The agreement announced by US President Donald Trump and judged as it should be “enormous” by the latter, “strengthens the hope of seeing other similar agreements concluded with other major economies on August 1,” observes John Plassard, Cité Management Management in charge of the investment strategy.
On the side of Wall Street, the main American clues finished in dispersed order on Tuesday, the S&P 500 reaching a record level, while the Nasdaq 100 fell before the publication of the key results of alphabet and Tesla. Technological values have weighed on the Nasdaq.
On the commercial front precisely, President Trump also announced an agreement with the Philippines providing for a customs duties of 19%, although Manila’s confirmation is pending. At the same time, the Treasury Secretary Scott Bessent said that the United States was likely to extend the deadline for customs duties with China and that he planned to meet Chinese officials next week in Stockholm.
This Wednesday, investors will still monitor real estate statistics in the United States and consumer confidence in Europe.
After starting on a rebound of 0.93%, the SMI accelerated again in the first exchanges, the flagship index crossing the threshold of 12,000 points and noting around 9:15 am to 12,045.38 points, a gain of 1.26%. The SLI also increased by 1.22% to 1997.19 points, while the enlarged SPI indicator advanced 1.09% to 16,800.07 points.
Of the thirty -one constitutive values of the Swiss Leader Index, only two lost ground, the other 29 by taking. At the bottom of the ranking, Vat Group (-2.8%) inherited the red lantern, behind the Swisscom defensive (-0.2%). The empty pump equipment manufacturer has certainly increased its sales and its profit in the first half of 2025, despite the global uncertainties, but orders have been packed much more strongly than expected by analysts. The St-Gallois group has nevertheless confirmed its forecasts for the year.
At the top of the ranking, Lonza (+6.1%) escaped alone in mind. The Pharma subcontractor has garnered highly increased revenues in the first half, carried by the growth of his core business. The annual financial, revenue and operating margin objectives are in the process revised upwards for its flagship segment. ALCON (+2.3%), Swatch Group (+2%) and Straumann (+1.9%) had launched in pursuit of the Rhénan group.
The heavy goods vehicle good (+1.4%) also appeared in a good position. The Board of Directors of the Giant Pharma reported Tuesday evening of a proposal in the General Assembly of March 20, 2026 to modernize the structure of the capital by transforming the pleasures of a nominal value of a nominal value of 0.001 francs. As long as they give their green light, the rock owners will receive by action a reimbursement of nominal value of 0.999 francs, or a total amount of more than 106.5 million francs.
The other two largest capitalizations on the coast, Nestlé (+0.7%) and Novartis (+1.2%) participated in the party, in moderation however.
On the extended market, Temenos took off almost 18%. The editor of banking software unveiled Tuesday evening a turnover in clear growth in the second quarter of 2025, its performance going far beyond the forecasts of market experts.
EFG International (+4.2%) also used clearly. The fortune manager recorded a record net profit over the first six months of the year. Management says it is confident to exceed its 2025 objectives.
Among the losers at the start of the session, V-Zug tumbled 7.8%. The appliance manufacturer experienced a difficult first semester, its flexing sales by 4.5%, while the EBIT collapsed by 66% and the net profit was divided by more than five. MedMix (-4.8%) and AMS OSRAM (-4.3%) also appeared, after their half-yearly performance.
Cosmo (-0.6%) saw its recipes fall after six months, but the Pharma Italian-Irlandais laboratory, with the maintenance of strict management of its costs, noted its objectives for 2025. (AWP)
